OPPM
IONS icon

Opus Point Partners Management’s Ionis Pharmaceuticals IONS Stock Holding History

Opus Point Partners Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.21M Hold
20,124
– – 2.18% 9
2019
Q2 		$1.29M Hold
20,124
– – 1.91% 9
2019
Q1 		$1.63M Sell
20,124
-2,183
-10% -$141K 2.21% 6
2018
Q4 		$1.21M Sell
22,307
-986
-4% -$50.3K 2.65% 8
2018
Q3 		$1.2M Sell
23,293
-623
-3% -$29.3K 2.87% 10
2018
Q2 		$997K Buy
23,916
+783
+3% +$34.7K 2.16% 19
2018
Q1 		$1.02M Sell
23,133
-16,255
-41% -$826K 2% 15
2017
Q4 		$1.98M Sell
39,388
-4,795
-11% -$263K 1.71% 19
2017
Q3 		$2.24M Buy
44,183
+316
+0.7% +$16.6K 2.01% 19
2017
Q2 		$2.23M Sell
43,867
-35,033
-44% -$1.63M 2.04% 18
2017
Q1 		$3.17M Buy
78,900
+1,350
+2% +$60.6K 2.35% 21
2016
Q4 		$3.71M Buy
77,550
+1,111
+1% +$44K 2.95% 7
2016
Q3 		$2.8M Buy
76,439
+5,571
+8% +$174K 1.57% 26
2016
Q2 		$1.65M Sell
70,868
-25,940
-27% -$837K 1.59% 26
2016
Q1 		$3.92M Sell
96,808
-5,651
-6% -$230K 3.03% 10
2015
Q4 		$6.34M Buy
102,459
+1,058
+1% +$57.1K 4.19% 3
2015
Q3 		$4.1M Buy
101,401
+35,193
+53% +$1.82M 2.26% 20
2015
Q2 		$3.81M Buy
66,208
+5,296
+9% +$337K 3.02% 18
2015
Q1 		$3.88M Buy
60,912
+15,494
+34% +$1.05M 3.25% 11
2014
Q4 		$2.8M Buy
+45,418
New +$2.24M 2.77% 17

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Opus Point Partners Management's IONS Position: Q3 2019 in Review

Opus Point Partners Management held its Ionis Pharmaceuticals (IONS) position steady in Q3 2019 at 20,124 shares worth $1.21M. The position accounts for 2.18% of the portfolio, ranked #9.

Opus Point Partners Management first reported a position in IONS in Q4 2014 and has held it in 20 quarters since. The position peaked at $6.34M in Q4 2015. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

  • Opus Point Partners Management held 20,124 shares of Ionis Pharmaceuticals worth $1.21M as of Q3 2019.
  • Opus Point Partners Management left its Ionis Pharmaceuticals share count unchanged in Q3 2019.
  • Ionis Pharmaceuticals made up 2.18% of Opus Point Partners Management's portfolio in Q3 2019, its #9 holding.
  • Opus Point Partners Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Opus Point Partners Management's Ionis Pharmaceuticals position peaked at $6.34M in Q4 2015.
  • 369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.